D. E. Shaw & Co., Inc. Kezar Life Sciences, Inc. Transaction History

D. E. Shaw & Co., Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.6 - $0.92 $103,550 - $158,777	-172,584 Reduced 41.15%	246,841 $148,000
Q1 2024 May 15, 2024	BUY	$0.8 - $1.05 $33,959 - $44,571	42,449 Added 11.26%	419,425 $377,000
Q4 2023 Feb 14, 2024	BUY	$0.72 - $1.15 $239,976 - $383,296	333,301 Added 763.14%	376,976 $358,000
Q3 2023 Nov 14, 2023	BUY	$1.08 - $2.54 $16,966 - $39,903	15,710 Added 56.18%	43,675 $51,000
Q2 2023 Aug 14, 2023	BUY	$2.31 - $3.06 $64,599 - $85,572	27,965 New	27,965 $68,000
Q2 2022 Aug 15, 2022	SELL	$4.58 - $17.13 $435,196 - $1.63 Million	-95,021 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$12.3 - $18.33 $1.17 Million - $1.74 Million	95,021 New	95,021 $1.58 Million

38.4M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $446M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.